Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Travere Therapeutics by 33.6% during Q1, owning approximately $6.07 million worth of the company's shares.
• CEO Eric M. Dube sold 18,924 shares of Travere stock at an average price of $21.05, resulting in a 4.32% decrease in his holding.
• Travere Therapeutics reported earnings per share of ($0.47) for the last quarter, surpassing analysts' estimates, with a revenue of $81.73 million—an increase of 83.3% year-over-year.

Universal Beteiligungs und Servicegesellschaft mbH grew its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Free Report) by 33.6% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 338,850 shares of the company's stock after purchasing an additional 85,228 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.38% of Travere Therapeutics worth $6,072,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in shares of Travere Therapeutics during the fourth quarter worth about $31,000. Sterling Capital Management LLC boosted its stake in shares of Travere Therapeutics by 859.8% during the fourth quarter. Sterling Capital Management LLC now owns 2,361 shares of the company's stock worth $41,000 after buying an additional 2,115 shares during the period. Gen Wealth Partners Inc acquired a new stake in shares of Travere Therapeutics during the fourth quarter worth about $73,000. KBC Group NV acquired a new stake in shares of Travere Therapeutics during the first quarter worth about $75,000. Finally, Summit Investment Advisors Inc. boosted its stake in shares of Travere Therapeutics by 9.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,905 shares of the company's stock worth $138,000 after buying an additional 667 shares during the period.

Analyst Upgrades and Downgrades

TVTX has been the subject of a number of research analyst reports. Canaccord Genuity Group increased their target price on shares of Travere Therapeutics from $45.00 to $47.00 and gave the company a "buy" rating in a report on Thursday, April 10th. Scotiabank reissued an "outperform" rating on shares of Travere Therapeutics in a research note on Friday, April 11th. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Travere Therapeutics in a research note on Tuesday, July 1st. Guggenheim reissued a "buy" rating and set a $47.00 price objective on shares of Travere Therapeutics in a research note on Monday, April 14th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Travere Therapeutics in a research note on Wednesday, April 23rd. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $32.14.

Insider Buying and Selling

In other news, CEO Eric M. Dube sold 18,924 shares of the stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $21.05, for a total value of $398,350.20. Following the transaction, the chief executive officer directly owned 419,173 shares of the company's stock, valued at $8,823,591.65. This represents a 4.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Peter Heerma sold 1,771 shares of the firm's stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $21.05, for a total transaction of $37,279.55. Following the completion of the transaction, the insider directly owned 128,215 shares in the company, valued at approximately $2,698,925.75. This represents a 1.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,294 shares of company stock worth $485,123. 4.19% of the stock is owned by insiders.

Travere Therapeutics Stock Up 0.7%

Shares of Travere Therapeutics stock traded up $0.10 during midday trading on Thursday, reaching $15.58. 249,735 shares of the company's stock traded hands, compared to its average volume of 1,635,801. Travere Therapeutics, Inc. has a 52 week low of $7.93 and a 52 week high of $25.29. The company's 50 day simple moving average is $15.32 and its 200 day simple moving average is $17.89. The company has a debt-to-equity ratio of 9.46, a quick ratio of 2.03 and a current ratio of 2.05. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -5.52 and a beta of 0.72.

Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.55) by $0.08. Travere Therapeutics had a negative net margin of 82.88% and a negative return on equity of 1,179.73%. The firm had revenue of $81.73 million for the quarter, compared to analyst estimates of $77.44 million. During the same period in the previous year, the business earned ($1.76) earnings per share. The company's revenue for the quarter was up 83.3% compared to the same quarter last year. Equities analysts expect that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.